|
參考文獻 Agarwal, M. L., Agarwal, A., taylor, W. R., and Stark, G. R. (1995). P53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in the human fibroblasts. Proc Natl Acad Sci, USA 92: 8493-8497. Amiel, J., Bougeard G., Francannet C. et al. (2001). TP63 gene mutation in ADULT syndrome. Europ J Hum Genet 9: 642-645. Amundson, S. A., Myers, T. G., Fornace, A. J. Jr. (1998). Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17: 3287-3299. Attardi, L. D., Lowe, S. W., Brugarolas, J., and Jacks, T., (1996). Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 15(14):3693-3701. Baskaran, R. (1997). Ataxia telangiectasia mutant protein activates c-Ab1 tyrosine kinase in response to ionizing radiation. Nature 387: 516-519. Bernstein GS et al, (1991). Male factor infertility. In: Mishell Jr DR, Davajan V, Lobo RA eds. Infertility, Contraception and Reproductive Endocrinolgy. 3rd Ed. P599-611. Bouck, N., (1996). P53 and angiogenesis. Biochim Biophys Acta 1287:63-66. Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., and Reddel, R. R., (1995). Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14: 4240-4248. Cheng, R., Ford B. L., O’Neal, P. E. et al. (1997). Zebrafish p53 tumor suppressor gene: cDNA sequence and expression during embryogenesis. Mol Mar Biol Biotechnol 6(2): 88-97. Chen, P. L., Chen, Y. M., Bookstein, R., and Lee, W. H., (1990). Genetic mechanisms of tumor suppression by the human p53 gene. Sciene 250: 1576-1580. Corn, P. G., Kuerbitz, S. J., van Noesel, M. M. et al. (1999). transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’CpG island methylation. Cancer Res 59, 3352-3356. Deleo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., and Old, L. J., (1979). Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci, USA 76: 2420-2424. Diller, L., Kassel, J., and Nelson, C. E., (1990). P53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772-5781. Donehower, L. A., (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221. Finlay, C. A., Hinds, P.W., and Levine, A.J., (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., and Sorlie, T., (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551-3555. Hollstein, M., Shomer, B., Greenblatt, M. S., Soussi, T., Hovig, E., Montesano, R., and Harris, C. C. (1996). Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24(1): 141-146. Ikawa, S., Nakagawara, A., Ikawa, Y., (1999). p53 family genes: structural comparison, expression and mutation. Cell Death Differ 6: 1154-1161. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W., (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311. Lane, D. P., (1992). p53, guardian of the genome. Nature 358: 15-16. Lee, C. W. and La Thangue, N. B. (1999). Promoter specificity and stability control of the p53 related protein p73. Oncogene 18: 4171-4178. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D., (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935. Kaghad, M., Bonnet, H., Yang, A., et al. (1997). monoallelically expressed gene related to p53 at 1p36, a region frequently delected in neuroblastoma and other human cancers. Cell 90: 809-819. Ko, L. J., and Prives, C., (1996). p53: Puzzle and paradigm. Gene Dev 10: 1054-1072. Maltzman, W., and Czyzyk, L., (1984). UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4: 1689-1694. Marin, M. C., Jost C. A., Irwin, M. S., DeCaprio, J. A., Caput, D., Kaelin, W. G. Jr., et al. 1998. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 18: 6316-6324. McGrath, J. A., Duijf, P. H., Doetsch, V., et al. (2001). Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Molec Genet 10: 221-229. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romano, J. W., and Ullrich, S. J., (1990). Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci, USA 87: 6166-6170. Miller, C., Mohanadas, T., Wolf, D., Prokocimer, M., Rotter, V., and Koeffler, H. P., (1986). Human p53 gene localized to short arm of chromosome 17. Nature 319: 783-784. Nomoto, S., Haruki, N., Kondo, M., et al. (1998). Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58: 1380-1383. Osada, M., Ohba, M., Kawahara, C., et al. (1998). Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med 4: 839-843. Oren, M., Reich, N. C., and Levine, A. J., (1982). Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol 2: 443-449. Reznikov, M., Fidler, R., Rubtsov, P. M., Skriabin, K. G., Chumakov, P. M., Prasolov, V. S., and Baev, A. A., (1989). Expression of human growth hormone in cultured mouse fibroblast. Molekuliarnaia Biol (Mosk) 23:1692-1699. Rogel, A., Popliker, M., Webb, C. G., and Oren, M. (1985). p53 cellular tumor antigen: analysis of mrna levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5: 2851-2855. Prives, C., and Manfredi, J. J., (1993). The p53 tumor suppressor protein: meeting review. Genes & Dev 7: 529-534. Soussi, T., and May, P., (1996). Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol 260: 623-637. Soussi, T., Caron, de, Fromentel, C., and May, P., (1990). Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-952. Strano, S., Rossi, M., Fontemaggi, G., et al. (2001). From p63 to p53 across p73. FEBS Letters 490: 163-170. Vojta, P. J., and Barrett, J. C., (1995). Genetic analysis of cellular senescence. Biochimica, et Biophysica, Acta 1242: 29-41. Yang, A. Kaghad, M., Wang, Y., et al., (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Molecular cell 2: 305-316. Yang, A., Schweitzer, R., Sun, D., et al., (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718. Yang, A., Walker, N., Bronson, R., et al., (2000). P73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature 404: 99-103 Yen SSC, Jaffe RB editors: Reproductive endocrinology: physiology, pathophysiology, and clinical management. Philadelphia, PA, 1991
|